1|ENGROSSED HOUSE | |BILL NO. 1416 By: West (Josh) and Fugate of | 2| the House | | | 3| and | | | 4| Rosino of the Senate | | | 5| | | | 6| | | | 7| | | | 8| [ non-opioid treatment preferred drug lists - | | | 9| coverage - United States Food and Drug | | | 10| Administration reimbursement codification - | | | 11| effective date ] | | | 12| | | | 13| | | | 14|BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: | | | 15| SECTION 1. NEW LAW A new section of law to be codified | | | 16|in the Oklahoma Statutes as Section 1313.1 of Title 74, unless there | | | 17|is created a duplication in numbering, reads as follows: | | | 18| A. As used in this section: | | | 19| 1. "Group insurance plan" means a group insurance plan that | | | 20|covers state employees; | | | 21| 2. "Health care prescriber" means an individual authorized by | | | 22|law to prescribe drugs; | | | 23| 3. "Insurer" means an insurer that offers a group insurance | | | 24|plan; and | | | arsid222859 ENGR. H. B. NO. 1416 Page 1 ___________________________________________________________________________
1| 4. "Non-opioid treatment" means a drug or biological product | | | 2|that is indicated to produce analgesia without acting on the body's | | | 3|opioid receptors, for which there is no other drug or product that | | | 4|is rated as therapeutically equivalent under the Food and Drug | | | 5|Administration's most recent publication of "Approved Drug Products | | | 6|with Therapeutic Equivalence Evaluations". | | | 7| B. Except as otherwise provided in this section, an insurer, | | | 8|for purposes of offering a group insurance plan, may adopt or amend | | | 9|a state preferred drug list (PDL). | | | 10| C. 1. In establishing and maintaining the PDL, the insurer | | | 11|shall ensure that a non-opioid drug approved by the United States | | | 12|Food and Drug Administration for the treatment or management of pain | | | 13|is not disadvantaged or discouraged with respect to coverage | | | 14|relative to an opioid or narcotic drug for the treatment or | | | 15|management of pain on the PDL. | | | 16| 2. Paragraph 1 of this subsection does not prohibit an opioid | | | 17|medication from being preferred over other opioid medications, or a | | | 18|non-opioid medication from being preferred over other non-opioid | | | 19|medications. | | | 20| D. This section applies to a non-opioid treatment as defined in | | | 21|paragraph 4 of subsection A of this section that has been reviewed | | | 22|and approved for coverage by a group insurance plan or insurer as | | | 23|defined in subsection A of this section. This section also applies | | | 24| | | | arsid222859 ENGR. H. B. NO. 1416 Page 2 ___________________________________________________________________________
1|to drugs being provided under a contract between the insurer and a | | | 2|pharmacy benefits manager for purposes of a group insurance plan. | | | 3| SECTION 2. This act shall become effective November 1, 2025. | | | 4| Passed the House of Representatives the 3rd day of March, 2025. | | | 5| | | | 6| | | Presiding Officer of the House | 7| of Representatives | | | 8| | | Passed the Senate the _____ day of __________, 2025. | 9| | | | 10| | | | 11| Presiding Officer of the Senate | | | 12| | | | 13| | | | 14| | | | 15| | | | 16| | | | 17| | | | 18| | | | 19| | | | 20| | | | 21| | | | 22| | | | 23| | | | 24| | | | arsid222859 ENGR. H. B. NO. 1416 Page 3